Free tool
FAERS Monitor: Tolsura
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208901 or its brand name (Tolsura, Itraconazole). Reports on generic versions are filed under their own applications.
Reports
9,411
Serious
8,437
90% of reports
Hospitalization
3,574
Death reported
1,977
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,040
- drug interaction1,022
- off label use518
- pyrexia494
- pneumonia412
- febrile neutropenia341
- nausea334
- dyspnoea333
- condition aggravated320
- diarrhoea304
- neutropenia276
- anaemia251
- sepsis247
- fatigue243
- rash236
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 146 |
| 2005 | 96 |
| 2006 | 146 |
| 2007 | 189 |
| 2008 | 208 |
| 2009 | 288 |
| 2010 | 250 |
| 2011 | 555 |
| 2012 | 464 |
| 2013 | 312 |
| 2014 | 286 |
| 2015 | 446 |
| 2016 | 341 |
| 2017 | 431 |
| 2018 | 589 |
| 2019 | 661 |
| 2020 | 712 |
| 2021 | 659 |
| 2022 | 538 |
| 2023 | 569 |
| 2024 | 524 |
| 2025 | 527 |
| 2026 | 473 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,748 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug interactionSignal | 1,022 | 14.5 | 13.7 | 12,830 |
| febrile neutropeniaSignal | 341 | 11.5 | 10.4 | 3,267 |
| sepsisSignal | 247 | 5.0 | 4.4 | 779 |
| neutropeniaSignal | 276 | 4.5 | 4.0 | 763 |
| pyrexiaSignal | 494 | 3.2 | 2.9 | 754 |
| anaemiaSignal | 251 | 2.9 | 2.6 | 323 |
| pneumoniaSignal | 412 | 2.8 | 2.6 | 499 |
| condition aggravatedSignal | 320 | 2.4 | 2.1 | 251 |
| drug ineffective | 1,040 | 1.8 | 1.7 | 366 |
| off label use | 518 | 1.3 | 1.2 | 42 |
| dyspnoea | 333 | 1.3 | 1.2 | 25 |
| rash | 236 | 1.2 | 1.1 | 9 |
| diarrhoea | 304 | 1.1 | 0.9 | 1 |
| nausea | 334 | 0.9 | 0.8 | 1 |
| fatigue | 243 | 0.7 | 0.6 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.